Northwest Bancshares Inc. boosted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 18.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,456 shares of the medical research company’s stock after acquiring an additional 2,272 shares during the quarter. Amgen comprises about 1.4% of Northwest Bancshares Inc.’s investment portfolio, making the stock its 15th biggest position. Northwest Bancshares Inc.’s holdings in Amgen were worth $2,814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. UNIVEST FINANCIAL Corp increased its stake in Amgen by 1.5% during the fourth quarter. UNIVEST FINANCIAL Corp now owns 23,544 shares of the medical research company’s stock worth $4,583,000 after acquiring an additional 355 shares during the last quarter. Pensionfund DSM Netherlands bought a new stake in Amgen during the fourth quarter worth approximately $3,738,000. Congress Asset Management Co. MA increased its stake in Amgen by 0.8% during the fourth quarter. Congress Asset Management Co. MA now owns 40,627 shares of the medical research company’s stock worth $7,909,000 after acquiring an additional 311 shares during the last quarter. Ferguson Wellman Capital Management Inc. increased its stake in Amgen by 0.6% during the fourth quarter. Ferguson Wellman Capital Management Inc. now owns 208,173 shares of the medical research company’s stock worth $40,525,000 after acquiring an additional 1,253 shares during the last quarter. Finally, Consolidated Investment Group LLC increased its stake in Amgen by 7.2% during the fourth quarter. Consolidated Investment Group LLC now owns 22,434 shares of the medical research company’s stock worth $4,367,000 after acquiring an additional 1,500 shares during the last quarter. 77.96% of the stock is currently owned by institutional investors.

Several equities research analysts have weighed in on the company. Goldman Sachs Group reissued a “buy” rating and set a $232.00 price objective on shares of Amgen in a research note on Tuesday, December 4th. Barclays reissued a “neutral” rating and set a $195.00 price objective on shares of Amgen in a research note on Tuesday, December 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $223.00 price objective on shares of Amgen in a research note on Tuesday, December 4th. JPMorgan Chase & Co. set a $192.00 price objective on Amgen and gave the stock a “neutral” rating in a research note on Tuesday, December 4th. Finally, Royal Bank of Canada reissued a “neutral” rating and set a $182.00 price objective on shares of Amgen in a research note on Tuesday, December 4th. Twelve analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $209.79.

In other news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $190.00, for a total transaction of $380,000.00. Following the transaction, the director now owns 14,988 shares of the company’s stock, valued at $2,847,720. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.27% of the company’s stock.

AMGN opened at $191.12 on Thursday. The company has a market cap of $119.16 billion, a PE ratio of 13.27, a price-to-earnings-growth ratio of 2.34 and a beta of 1.21. Amgen, Inc. has a one year low of $163.31 and a one year high of $210.19. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.16. The firm had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same quarter in the prior year, the firm posted $2.89 earnings per share. As a group, equities research analysts predict that Amgen, Inc. will post 13.97 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.03%. Amgen’s dividend payout ratio is 40.28%.

TRADEMARK VIOLATION NOTICE: “Northwest Bancshares Inc. Has $2.81 Million Holdings in Amgen, Inc. (AMGN)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/03/21/northwest-bancshares-inc-has-2-81-million-holdings-in-amgen-inc-amgn.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Why Invest in Dividend Achievers?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.